文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌放疗联合ADT:系统综述与荟萃分析

ADT Combinations With Radiation for Prostate Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-07-19

该系统综述与荟萃分析评估局限期前列腺癌放疗联合雄激素剥夺治疗(ADT)时,联用或不联用第一代非甾体抗雄激素(NSAA)对总生存、其他原因死亡和毒性的影响。延长LHRHa疗程与总生存改善相关,但延长NSAA疗程未显示总生存获益,且与早期ADT停药风险升高相关。

要点

  • 延长LHRHa疗程与总生存改善相关,延长NSAA疗程则无总生存获益。
  • 延长NSAA疗程与早期ADT停药风险升高相关,但置信区间较宽。
  • 数据未显示延长NSAA与毒性增加有明确关联。

核心结论

  • 延长NSAA疗程与LHRHa联用时未显示总生存获益。
  • 有信号提示加用NSAA可能导致早期ADT停药,但数据未明确显示延长NSAA与毒性增加相关。
  • 建议与LHRHa联用时考虑限制NSAA的疗程。

研究设计与样本

  • 系统检索1966年至2026年3月间评估局限期前列腺癌根治性或挽救性放疗联合ADT(联用或不联用NSAA)疗程的研究。
  • 排除包含第二代NSAA、手术去势、终身ADT或间歇性ADT的试验。
  • 采用PRISMA指南提取数据并评估质量,由2名观察者独立提取,使用随机效应模型合并数据。
  • 结局包括总生存、其他原因死亡和毒性。

主要发现

  • 延长LHRHa疗程与总生存改善相关。
  • 较长的NSAA或LHRHa疗程与其他原因死亡无显著关联。

关键数值与推荐

  • 推荐与LHRHa联用时考虑限制NSAA的疗程。

临床怎么用

  • 局限期前列腺癌放疗联合ADT时,延长LHRHa疗程可改善总生存。
  • 与LHRHa联用时,延长NSAA疗程未显示总生存获益,且可能增加早期ADT停药风险,应考虑限制NSAA疗程。

局限性

  • 早期ADT停药的估计值不精确且置信区间宽。
  • 数据未显示延长NSAA与毒性增加有明确关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is substantially heterogeneous use of luteinizing hormone-releasing hormone analogs (LHRHa) with or without first-generation nonsteroidal antiandrogens (NSAA, eg, bicalutamide) during radiation for localized prostate cancer. The primary objectives of this study were to determine the impact of NSAA on overall survival (OS), other-cause mortality, and toxicity. METHODS AND MATERIALS: We performed a systematic search of studies conducted between 1966 and March 2026 evaluating androgen deprivation therapy (ADT) duration, with or without NSAA, when combined with definitive or salvage radiation therapy for localized prostate cancer. Trials including second-generation NSAA, surgical castration, lifelong ADT, or intermittent ADT were excluded. PRISMA guidelines were used for abstracting data and assessing data quality and validity, with independent extraction by 2 observers. Data were pooled using a random-effects model. RESULTS: Although prolonging LHRHa duration was associated with improved OS, prolonging NSAA was not (ref 1-2 months; 3-5-month NSAA hazard ratio, 1.54, 95% CI, 0.97-2.44, P = .07; ≥6-month NSAA hazard ratio, 1.68, 95% CI, 1.07-2.63, P = .02). Longer durations of NSAA or LHRHa were not significantly associated with other-cause mortality. Prolonging NSAA duration was associated with higher odds of early ADT discontinuation (ref 0-2-month NSAA; 3-5-month odds ratio, 5.05, 95% CI, 1.21-21.16, P = .03; 6-9 months, 3.97, 95% CI, 0.94-16.67, P = .06), although estimates were imprecise with wide confidence intervals. CONCLUSIONS: This meta-analysis demonstrates a lack of OS benefit to prolonging NSAA duration when used with LHRHa. There is some signal that adding NSAA contributes to early ADT discontinuation, but our data did not show a clear signal that prolonging NSAA was associated with increased toxicity. Providers should consider limiting the duration of NSAA if used in combination with LHRHa.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Takayesu JSK, Xie T, Aldous J, et al. ADT Combinations With Radiation for Prostate Cancer: A Systematic Review and Meta-analysis. Int J Radiat Oncol Biol Phys. 2026. PMID: 42472616. doi:10.1016/j.ijrobp.2026.06.3095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。